![[D-p-Cl-Phe6,Leu17]-VIP TFA](https://file.medchemexpress.com/product_pic/hy-p1159a.gif "Click to View [D-p-Cl-Phe6,Leu17]-VIP TFA Product Detail")
![[K15,R16,L27]VIP(1-7)/GRF(8-27) acetate](https://file.medchemexpress.com/product_pic/hy-p4195a.gif "Click to View [K15,R16,L27]VIP(1-7)/GRF(8-27) acetate Product Detail")
![[D-p-Cl-Phe6,Leu17]-VIP](https://file.medchemexpress.com/product_pic/hy-p1159.gif "Click to View [D-p-Cl-Phe6,Leu17]-VIP Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
67 Results for "
VIP
" in MedChemExpress (MCE) Product Catalog:
Products (67)
67 Results for "VIP" in MCE Product Catalog:
5
5 Cited Publications
Art. -Nr.: HY-P0221
CAS. Nr.: 137061-48-4
Synonyms: Pituitary Adenylate Cyclase Activating Polypeptide 38
Forschungsgebiete:
2
2 Cited Publications
Art. -Nr.: HY-P0012
CAS. Nr.: 40077-57-4
Synonyms: Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)
Target:
Forschungsgebiete:
2
2 Cited Publications
Synonyms: (+)-BAY-1251152; (+)-VIP152; (S)-Enitociclib
Target:
Forschungsgebiete:
Enitociclib ((+)-BAY-1251152; (+)-VIP152) is a selective CDK9 inhibitor (IC50=3 nM) that inhibits transcriptional elongation by blocking Ser2/Ser5 phosphorylation of RNA polymerase II. Enitociclib specifically depletes key short-lived proteins such as c-MYC, MCL-1 and induces tumor cell apoptosis. Enitociclib also interferes with the production of enhancer RNAs (eRNA) and enhancer-promoter interactions, and downregulates oncogene expression at the epigenetic level. Enitociclib exerts synergistic effects with agents including Bortezomib (HY-10227), Lenalidomide (HY-A0003), Pomalidomide (HY-10984), Venetoclax (HY-15531) and Paclitaxel (HY-B0015), and even reverses paclitaxel resistance. Enitociclib serves as a vital research tool for various malignancies such as double-hit diffuse large B-cell lymphoma, multiple myeloma and pancreatic ductal adenocarcinoma .
2
2 Cited Publications
Art. -Nr.: HY-P0220A
Target:
Forschungsgebiete:
2
2 Cited Publications
Art. -Nr.: HY-P0220
CAS. Nr.: 143748-18-9
Target:
Forschungsgebiete:
2
2 Cited Publications
Synonyms: (R)-Enitociclib; (-)-BAY-1251152; (-)-VIP152
Target:
Forschungsgebiete:
(-)-Enitociclib ((R)-Enitociclib) is an enantiomer of Enitociclib (HY-103019E) with an optical rotation of (-). Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC + lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies .
2
2 Cited Publications
Art. -Nr.: HY-P0012A
CAS. Nr.: 1444827-29-5
Synonyms: Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)
Target:
Forschungsgebiete:
1
1 Cited Publications
Art. -Nr.: HY-P1023
CAS. Nr.: 69698-54-0
Target:
Forschungsgebiete:
1
1 Cited Publications
Art. -Nr.: HY-P1159A
Target:
Forschungsgebiete:
1
Synonyms: (±)-BAY-1251152; (±)-VIP152
Target:
Forschungsgebiete:
(±)-Enitociclib ((±)-BAY-1251152) is the racemic mixture of Enitociclib (HY-103019E). Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC + lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies .
Art. -Nr.: HY-P0221C
CAS. Nr.: 129405-61-4
Target:
Forschungsgebiete:
Art. -Nr.: HY-P5005
CAS. Nr.: 125093-93-8
Target:
Forschungsgebiete:
Art. -Nr.: HY-P11288
CAS. Nr.: 2871680-36-1
Target:
Forschungsgebiete:
Art. -Nr.: HY-P11288A
Target:
Forschungsgebiete:
Art. -Nr.: HY-P4195A
Target:
Forschungsgebiete:
Art. -Nr.: HY-P10948A
Target:
Forschungsgebiete:
Art. -Nr.: HY-P4776
CAS. Nr.: 202463-00-1
Target:
Forschungsgebiete:
Art. -Nr.: HY-P1159
CAS. Nr.: 102805-45-8
Target:
Forschungsgebiete:
Art. -Nr.: HY-P4127A
Target:
Forschungsgebiete:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
